A New Dawn for IgA Nephropathy – Redefining What is Possible with Sparsentan Presented by Travere and ISN
March 11, 2025
Virtual
Mechanism of Protective Actions of Sparsentan in the Kidney: Lessons From Studies in Models of Chronic Kidney Disease
Long-Term Outcomes in IgA Nephropathy
Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results From a Randomised Active-Controlled Phase 3 Trial